Headquartered in San Diego, CA Fiscal year ends December NASDAQ: DXCM dexcom.com
DexCom, Inc. develops and sells biosensing technology, primarily continuous glucose monitoring (CGM) systems used by people with diabetes and by consumers tracking their glucose. Founded in 1999, the company has worked in glucose biosensing for more than 25 years.
Its product portfolio includes:
- The Dexcom G7 CGM, including the extended-wear Dexcom G7 15 Day System, which is rolling out in the U.S. and has received its first international regulatory clearances.
- Stelo, a glucose biosensor and app experience offering glucose insights, meal logging and nutritional information.
Dexcom sells mainly through distributors, with a smaller direct channel, in the United States and international markets. The U.S. accounts for the majority of revenue. The company is expanding its clinical evidence base into Type 2 diabetes patients not on insulin, highlighted by the CONNECT randomized trial published in The New England Journal of Medicine. It is also expanding production capacity and returns capital through share repurchases. Updated
Dexcom raised full-year revenue guidance again, to $5.20 billion to $5.25 billion, after topping expectations on both lines. Management also lifted non-GAAP operating margin guidance to about 24% and authorized a new $1.0 billion buyback.
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it…
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise…
Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran’s peace…
Pre-Market Stock Futures: The futures are lower on Tuesday after traders kicked off the holiday-shortened trading week with a massive Monday rally, with all major indices finishing the day higher. A combination…
In the past week or so, renowned investors Carl Icahn and Mario Gabelli led some huge insider buying. These were not the only notable purchases though.
Chase Coleman III is the founder of Tiger Global Management. Coleman’s hedge fund is a whale with nearly $56 billion in assets under management gathered from 42 wealthy clients. As 24/7 Wall…
Will Ashworth It’s time to buy on the dip. The only problem? There aren’t many to choose from. Of the 503 S&P 500 stocks, 229 are currently up more than 20% year-to-date, compared to…
Investors have been on a roller coaster ride for the past four years and the stock market may be heading into another big loop higher. Federal Reserve chairman Jay Powell gave his…
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Carnival, Deere, Delta Air Lines, DexCom, Enovix, First Republic Bank, GitLab, Hartford Financial Services, Interpublic Group, Invesco, Lululemon Athletica, Macy’s, Marathon Petroleum, Medtronic,…
U.S. equities are trading somewhat higher in Tuesday's premarket session as investors wait to hear what Federal Reserve chief Jerome Powell has to say to Congress.
Another cryptocurrency exchange is in hot water, and a little-known penny stock is making a big noise on a merger announcement.
Friday's top analyst upgrades and downgrades included Datadog, DexCom, Exelixis, Lam Research, Las Vegas Sands, Lyft, Match, Nasdaq, Next Era Energy, Norfolk Southern, Pfizer, Walmart and Wolfspeed.
After a horrific year in the markets, Jefferies has made some big changes to its Franchise Picks list of top stocks. These eight outstanding additions to the list have plenty of upside…
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, AES, Amazon.com, CommScope, Emerson Electric, Intel, Leslie’s, Microsoft, Paramount Global, Prologis, Rivian Automotive and Rocket Companies.
DexCom, Inc. develops and sells biosensing technology, primarily continuous glucose monitoring (CGM) systems used by people with diabetes and by consumers tracking their glucose. Founded in 1999, the company has worked in glucose biosensing for more than 25 years.
24/7 Wall St.'s 12-month price target for DXCM is $103.11, rated Buy. The Wall Street consensus target is $96.19. DXCM price prediction →
